| Cash Flow | 2025-09-27 | 2025-06-28 |
|---|---|---|
| Product sales | 24,388,272 | - |
| Cost of product sales | 20,318,390 | - |
| Gross profit | 4,069,882 | - |
| Selling, general, and administrative expenses | 3,527,223 | - |
| Income (loss) from operations | 542,659 | - |
| Other income, net | 114,985 | - |
| Net income (loss) before income taxes | 657,644 | - |
| Income tax provision (benefit) | 249,885 | - |
| Net income (loss) | 407,759 | 199,795 |
| Depreciation and amortization | 458,478 | 321,189 |
| Share-based compensation | 220,894 | 171,540 |
| Realized gain on sale of marketable securities | 11,470 | 12,183 |
| Deferred taxes | -249,429 | -135,828 |
| Accounts receivables-Trade Accounts Receivable | 541,872 | 744,495 |
| Accounts receivables-Other Receivables | 199,584 | 238,961 |
| Inventories | 1,052,615 | 867,180 |
| Prepaid expenses and other current assets | -152,736 | -217,350 |
| Accounts payable | 476,340 | 232,511 |
| Accrued expenses | 384,991 | 123,184 |
| Deferred revenue | -98,171 | -142,045 |
| Net cash provided by (used in) operating activities | 446,915 | -603,467 |
| Purchases of property and equipment | 439,492 | 265,918 |
| Acquisition cost of patents and trademarks | 25,905 | 21,363 |
| Proceeds from sale of marketable securities | 1,027,000 | 518,000 |
| Purchase of marketable securities | 1,046,933 | 525,772 |
| Net cash used in investing activities | -485,330 | -295,053 |
| Payments on note payable | 8,130 | 8,130 |
| Net cash used in financing activities | -8,130 | -8,130 |
| Net decrease in cash and cash equivalents | -46,545 | -906,650 |
| Cash and cash equivalents at beginning of period | 3,280,687 | - |
| Cash and cash equivalents at end of period | 3,234,142 | - |
CPS TECHNOLOGIES CORP DE (CPSH)
CPS TECHNOLOGIES CORP DE (CPSH)